Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 12 | 2021 | 778 | 1.810 |
Why?
|
| Brachytherapy | 4 | 2012 | 79 | 1.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 2014 | 332 | 1.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 467 | 0.910 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 475 | 0.750 |
Why?
|
| Chemoradiotherapy | 3 | 2016 | 54 | 0.710 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 30 | 0.580 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 39 | 0.510 |
Why?
|
| Cholecalciferol | 2 | 2012 | 143 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 444 | 0.440 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2010 | 36 | 0.440 |
Why?
|
| Radiotherapy, Conformal | 2 | 2012 | 24 | 0.440 |
Why?
|
| Lymph Nodes | 1 | 2014 | 258 | 0.430 |
Why?
|
| Salvage Therapy | 2 | 2012 | 82 | 0.430 |
Why?
|
| Particle Accelerators | 1 | 2012 | 10 | 0.420 |
Why?
|
| Watchful Waiting | 1 | 2012 | 25 | 0.410 |
Why?
|
| Androgen Antagonists | 3 | 2021 | 45 | 0.400 |
Why?
|
| Prostate | 1 | 2012 | 116 | 0.390 |
Why?
|
| Adenoma | 1 | 2012 | 132 | 0.380 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.370 |
Why?
|
| Dietary Supplements | 2 | 2012 | 331 | 0.360 |
Why?
|
| Rectal Neoplasms | 3 | 2016 | 75 | 0.340 |
Why?
|
| Models, Chemical | 2 | 2008 | 155 | 0.330 |
Why?
|
| Free Radicals | 1 | 2008 | 65 | 0.310 |
Why?
|
| Nucleotides | 1 | 2008 | 29 | 0.310 |
Why?
|
| DNA | 2 | 2008 | 597 | 0.300 |
Why?
|
| Aged | 11 | 2019 | 14842 | 0.270 |
Why?
|
| Male | 20 | 2021 | 37283 | 0.270 |
Why?
|
| Treatment Outcome | 7 | 2019 | 7028 | 0.250 |
Why?
|
| Middle Aged | 11 | 2016 | 21119 | 0.230 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2013 | 35 | 0.230 |
Why?
|
| Radiotherapy | 3 | 2018 | 86 | 0.220 |
Why?
|
| Humans | 26 | 2021 | 68549 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 36 | 0.210 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 125 | 0.210 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 100 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 18 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 11 | 0.190 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 15 | 0.190 |
Why?
|
| Trisomy | 1 | 2021 | 47 | 0.190 |
Why?
|
| Radiation Oncology | 2 | 2018 | 12 | 0.180 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 5 | 0.180 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 48 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 70 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 125 | 0.170 |
Why?
|
| Organ Specificity | 1 | 2018 | 167 | 0.150 |
Why?
|
| Serpins | 1 | 2019 | 205 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2018 | 97 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 1046 | 0.140 |
Why?
|
| Colostomy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Ileostomy | 1 | 2015 | 14 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 4843 | 0.130 |
Why?
|
| Capecitabine | 1 | 2014 | 11 | 0.120 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 21 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 191 | 0.120 |
Why?
|
| Female | 8 | 2021 | 38021 | 0.120 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 6 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 5 | 0.120 |
Why?
|
| Anilides | 1 | 2013 | 16 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 41 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.120 |
Why?
|
| Deoxycytidine | 1 | 2014 | 83 | 0.120 |
Why?
|
| Taxoids | 1 | 2013 | 41 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 91 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2014 | 130 | 0.110 |
Why?
|
| Nitriles | 1 | 2013 | 68 | 0.110 |
Why?
|
| SEER Program | 1 | 2014 | 150 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 274 | 0.110 |
Why?
|
| Propanolamines | 1 | 2013 | 70 | 0.110 |
Why?
|
| Calcitriol | 1 | 2013 | 106 | 0.110 |
Why?
|
| Amides | 1 | 2013 | 86 | 0.110 |
Why?
|
| Time Factors | 2 | 2012 | 4655 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.110 |
Why?
|
| Acid Ceramidase | 1 | 2013 | 85 | 0.110 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 135 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 216 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 791 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 138 | 0.100 |
Why?
|
| Computer Simulation | 2 | 2008 | 706 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2009 | 84 | 0.100 |
Why?
|
| Palladium | 1 | 2010 | 12 | 0.090 |
Why?
|
| Intraoperative Period | 1 | 2010 | 62 | 0.090 |
Why?
|
| Computer Systems | 1 | 2010 | 42 | 0.090 |
Why?
|
| Radioisotopes | 1 | 2010 | 40 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 119 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2012 | 447 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 285 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2010 | 132 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 32 | 0.090 |
Why?
|
| Monte Carlo Method | 2 | 2008 | 124 | 0.090 |
Why?
|
| Urinary Retention | 1 | 2009 | 20 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 1055 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 3 | 2016 | 104 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2013 | 753 | 0.080 |
Why?
|
| Anesthesia | 1 | 2010 | 120 | 0.080 |
Why?
|
| Equipment Design | 1 | 2010 | 500 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 32 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 57 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2009 | 419 | 0.080 |
Why?
|
| Risk Factors | 3 | 2016 | 5720 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1745 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 560 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 28 | 0.080 |
Why?
|
| Glioma | 1 | 2009 | 140 | 0.080 |
Why?
|
| Child | 4 | 2021 | 6401 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1664 | 0.070 |
Why?
|
| Androgens | 2 | 2021 | 41 | 0.070 |
Why?
|
| Rhabdomyosarcoma | 1 | 2006 | 36 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2021 | 7268 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2008 | 546 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 951 | 0.060 |
Why?
|
| Third-Party Consent | 1 | 2005 | 7 | 0.060 |
Why?
|
| Adult | 4 | 2015 | 21379 | 0.060 |
Why?
|
| Human Experimentation | 1 | 2005 | 19 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 371 | 0.060 |
Why?
|
| State Government | 1 | 2005 | 34 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 2891 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 3187 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2002 | 129 | 0.050 |
Why?
|
| Deoxyribose | 1 | 2002 | 3 | 0.050 |
Why?
|
| Hydroxyl Radical | 1 | 2002 | 17 | 0.050 |
Why?
|
| Prognosis | 2 | 2006 | 2093 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 33 | 0.050 |
Why?
|
| DNA Damage | 1 | 2002 | 190 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2021 | 312 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 561 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 349 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 84 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 284 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 499 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 848 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2356 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 33 | 0.030 |
Why?
|
| Adolescent | 2 | 2009 | 8904 | 0.030 |
Why?
|
| Calcium Channel Agonists | 1 | 2013 | 18 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 31 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 71 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
| Vimentin | 1 | 2013 | 47 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 49 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 118 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2013 | 64 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.030 |
Why?
|
| Cadherins | 1 | 2013 | 93 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 294 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 226 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 304 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 324 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 1425 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 852 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 710 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 614 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 954 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 770 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 630 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1027 | 0.020 |
Why?
|
| Medical Illustration | 1 | 2010 | 4 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2013 | 337 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 292 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1515 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 242 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 330 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1663 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 756 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 572 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 516 | 0.020 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2008 | 12 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 132 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 199 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 22 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 1037 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1738 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 1341 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2006 | 108 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 799 | 0.020 |
Why?
|
| Mental Competency | 1 | 2005 | 29 | 0.020 |
Why?
|
| Canada | 1 | 2005 | 266 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 539 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 3703 | 0.010 |
Why?
|
| Stochastic Processes | 1 | 2002 | 27 | 0.010 |
Why?
|
| Hydrogen | 1 | 2002 | 35 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2002 | 92 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 8474 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 5710 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 20880 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1195 | 0.010 |
Why?
|